Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative Assessment of GFAP-Based Astrocyte Morphology in the Cuprizone Model: A Comparative Evaluation of Neurolucida<sup>®</sup> 360 and SNT.

Cells·2026
Same author

Astrocytic Accumulation at the Choroid Plexus Attachment Region.

Cellular and molecular neurobiology·2026
Same author

Evaluation of lactic acid as a novel fixative for histological and neuroanatomical applications.

Scientific reports·2026
Same author

Loss of oligodendrocyte transcription factor 2 protein expression in metabolically stressed oligodendrocytes.

Acta neuropathologica·2026
Same author

Introduction of Universal WON-Point for Posterior Cranial Fossa Puncture in Monitoring Infratentorial Intracranial Pressure.

Operative neurosurgery (Hagerstown, Md.)·2026
Same author

Etranacogene dezaparvovec in people with hemophilia B with preexisting adeno-associated virus 5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trial.

Research and practice in thrombosis and haemostasis·2026
Same journal

Role of Cholesterol Metabolism in the Link Between Diabetes and Alzheimer's Disease.

CNS & neurological disorders drug targets·2026
Same journal

Linking Neurodegeneration and Age-related Macular Degeneration: Unified Pathways and Intervention Strategies.

CNS & neurological disorders drug targets·2026
Same journal

Modulating the Microbiota-gut-brain Axis: A Promising Strategy for Alzheimer's Disease Prevention and Management.

CNS & neurological disorders drug targets·2026
Same journal

The Therapeutic Effects of Dietary Supplements on OCD: A Narrative Review.

CNS & neurological disorders drug targets·2026
Same journal

Amyotrophic Lateral Sclerosis: Therapeutic Innovations and Evolving Regulatory Approaches.

CNS & neurological disorders drug targets·2026
Same journal

Pathogenic Proteins Driving ALS Pathogenesis: Molecular Mechanisms and Translational Therapeutic Perspectives.

CNS & neurological disorders drug targets·2026
See all related articles

Related Experiment Video

Updated: May 22, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Pathology of multiple sclerosis.

Markus Kipp1, Paul van der Valk, Sandra Amor

  • 1Department of Pathology, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands.

CNS & Neurological Disorders Drug Targets
|May 16, 2012
PubMed
Summary
This summary is machine-generated.

Pathological studies reveal multiple sclerosis (MS) involves inflammation, demyelination, and axonal damage. Recent findings highlight neurodegeneration and innate immunity

More Related Videos

An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices
06:36

An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices

Published on: February 5, 2015

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

Related Experiment Videos

Last Updated: May 22, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices
06:36

An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices

Published on: February 5, 2015

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

Area of Science:

  • Neuropathology
  • Immunology
  • Neuroscience

Background:

  • Multiple sclerosis (MS) is characterized by central nervous system (CNS) inflammation, demyelination, and axonal damage.
  • Current therapies target adaptive immune responses (T and B cells).
  • Emerging evidence suggests neurodegenerative aspects and innate immunity's role in MS.

Purpose of the Study:

  • To review recent neuropathological findings in MS.
  • To discuss the implications of these findings for future therapeutic strategies.

Main Methods:

  • Examination of affected human central nervous system (CNS) tissues.
  • Review of current scientific literature on MS neuropathology.

Main Results:

  • Pathological studies confirm inflammatory demyelination and axonal injury in MS.
  • Re-evaluation of neuropathology indicates significant neurodegenerative components.
  • Innate immunity is increasingly recognized as a key player in the MS disease process.

Conclusions:

  • The understanding of MS pathogenesis has shifted from a purely autoimmune model to one encompassing neurodegeneration and innate immunity.
  • Neuropathological insights are crucial for developing novel neuroprotective therapies for MS.